SI2104682T1 - Diagnostika in zdravljenje Alzheimerjeve bolezni in drugih nevrodementnih bolezni - Google Patents

Diagnostika in zdravljenje Alzheimerjeve bolezni in drugih nevrodementnih bolezni

Info

Publication number
SI2104682T1
SI2104682T1 SI200831731A SI200831731A SI2104682T1 SI 2104682 T1 SI2104682 T1 SI 2104682T1 SI 200831731 A SI200831731 A SI 200831731A SI 200831731 A SI200831731 A SI 200831731A SI 2104682 T1 SI2104682 T1 SI 2104682T1
Authority
SI
Slovenia
Prior art keywords
alzheimer
diagnosis
treatment
neurodementing
diseases
Prior art date
Application number
SI200831731A
Other languages
English (en)
Inventor
Richard Dodel
Michael Bacher
Michael Przybylski
Raluca Stefanescu
Marilena Manea
Original Assignee
Michael Bacher
Dodel, Richhard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07000507A external-priority patent/EP1944314A1/en
Priority claimed from EP07000521A external-priority patent/EP1944315A1/en
Application filed by Michael Bacher, Dodel, Richhard filed Critical Michael Bacher
Publication of SI2104682T1 publication Critical patent/SI2104682T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
SI200831731A 2007-01-11 2008-01-11 Diagnostika in zdravljenje Alzheimerjeve bolezni in drugih nevrodementnih bolezni SI2104682T1 (sl)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US88451307P 2007-01-11 2007-01-11
US88452607P 2007-01-11 2007-01-11
EP07000507A EP1944314A1 (en) 2007-01-11 2007-01-11 Diagnosis of Alzheimer's disease and other neurodementing disorders
EP07000521A EP1944315A1 (en) 2007-01-11 2007-01-11 Prophylaxis and therapy of alzheimer's disease and other neurodementing diseases
US98167507P 2007-10-22 2007-10-22
US98166707P 2007-10-22 2007-10-22
EP07119026 2007-10-22
EP07119002 2007-10-22
EP08719192.0A EP2104682B1 (en) 2007-01-11 2008-01-11 Diagnosis and treatment of alzheimer's and other neurodementing diseases
PCT/IB2008/000456 WO2008084402A2 (en) 2007-01-11 2008-01-11 Diagnosis and treatment of alzheimer's and other neurodementing diseases

Publications (1)

Publication Number Publication Date
SI2104682T1 true SI2104682T1 (sl) 2017-05-31

Family

ID=39609117

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200831731A SI2104682T1 (sl) 2007-01-11 2008-01-11 Diagnostika in zdravljenje Alzheimerjeve bolezni in drugih nevrodementnih bolezni

Country Status (11)

Country Link
US (3) US7939075B2 (sl)
EP (1) EP2104682B1 (sl)
JP (1) JP2010515717A (sl)
AU (1) AU2008204335B2 (sl)
CA (1) CA2675340C (sl)
DK (1) DK2104682T3 (sl)
ES (1) ES2610474T3 (sl)
PL (1) PL2104682T3 (sl)
SI (1) SI2104682T1 (sl)
TW (1) TW200844110A (sl)
WO (1) WO2008084402A2 (sl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090280114A1 (en) * 2002-04-12 2009-11-12 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1976877B2 (en) 2005-11-30 2016-10-05 AbbVie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
DK1954718T3 (en) 2005-11-30 2014-12-15 Abbvie Inc Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies,
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
EP2143447A1 (en) * 2008-07-11 2010-01-13 Universität Konstanz Bioconjugates comprising Aß-autoantibody-specific epitopes for active immunotherapy and diagnosis of Alzheimer's disease
CA2752373C (en) * 2009-02-20 2017-10-10 To-Bbb Holding B.V. Glutathione-based drug delivery system
KR101095630B1 (ko) * 2009-06-17 2011-12-19 주식회사 이노파마스크린 베타 아밀로이드 펩타이드와 ｖｅｇｆ의 상호작용을 억제하는 물질을 탐색 방법 및 그에 의해서 탐색된 저해제
DE102009034119A1 (de) * 2009-07-20 2011-01-27 Philipps-Universität Marburg Verfahren, insbesondere Enzyme-linked Immunosorbent Assay (ELISA), zum in vitro Nachweis von Amyloid beta Autoantikörpern, Mikrotiterplatte und Testkit
EP2921486B1 (en) 2009-08-07 2017-09-27 American Life Science Pharmaceuticals, Inc. Compositions and methods for treating beta-amyloid related diseases
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
PL2579042T3 (pl) * 2011-10-04 2014-12-31 Affiris Ag Sposób wykrywania przeciwciał swoistych wobec Aß w próbce biologicznej
KR101190573B1 (ko) * 2011-10-07 2012-10-18 대한민국 혈액 내 아밀로이드-베타 항체에 특이적으로 결합하는 신규 Ａβ２２（ｐＥ）－４２ 펩티드를 유효성분으로 포함하는 치매 진단용 키트
EP2825884A4 (en) * 2012-03-13 2015-11-11 Janssen Alzheimer Immunotherap A OLIGOMER FOR DIAGNOSIS, PROGNOSIS AND FOLLOW-UP OF ALZHEIMER'S DISEASE
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
JP6582995B2 (ja) 2014-01-21 2019-10-02 株式会社島津製作所 Ａｐｐ切断型ペプチドの測定方法
WO2016054114A1 (en) 2014-09-29 2016-04-07 The Regents Of The University Of California Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions
EP3043354B1 (en) * 2015-01-12 2018-01-03 Heraeus Deutschland GmbH & Co. KG Use of an electrically conductive composition as an electrically conductive adhesive for mechanically and electrically connecting electrical conductors to electrical contacts of solar cells
ES2834484T3 (es) 2016-11-21 2021-06-17 Univ Ruhr Bochum Método para la preselección de fármacos para enfermedades de plegamiento incorrecto de proteínas
US20210087280A1 (en) * 2017-12-19 2021-03-25 Surrozen, Inc. Anti-frizzled antibodies and methods of use
WO2019126401A1 (en) 2017-12-19 2019-06-27 Surrozen, Inc. Anti-lrp5/6 antibodies and methods of use
WO2019126398A1 (en) * 2017-12-19 2019-06-27 Surrozen, Inc. Wnt surrogate molecules and uses thereof
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
CA1339014C (en) 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
EP0683234B2 (en) * 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antibody against beta-amyloid or their derivative and use thereof
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1998044955A1 (en) 1997-04-09 1998-10-15 Mindset Ltd. Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
IL149976A0 (en) 1999-12-08 2002-12-01 Mindset Biopharmaceuticals Usa Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies
US20020182660A1 (en) 2000-02-18 2002-12-05 Fong Kei-Lai L. N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43)
US20030083277A1 (en) 2000-02-24 2003-05-01 Hersh Louis B. Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's disease in patients
CZ306683B6 (cs) 2000-02-24 2017-05-03 Washington University Léčivo pro prevenci nebo léčení preklinické nebo klinické Alzheimerovy nemoci
PT2275449T (pt) * 2000-06-16 2016-12-27 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
US20020009445A1 (en) 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
EP1172378A1 (en) 2000-07-12 2002-01-16 Richard Dr. Dodel Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
JP4317010B2 (ja) 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
US20030082191A1 (en) 2001-08-29 2003-05-01 Poduslo Joseph F. Treatment for central nervous system disorders
US20050208050A1 (en) * 2001-11-09 2005-09-22 Gerd Multhaup Compounds for the diagnosis/prevention/treatment of alzheimer's disease
WO2003051374A2 (en) 2001-12-17 2003-06-26 New York State Office Of Mental Health SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004013172A2 (en) 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
JP2006516535A (ja) 2002-09-12 2006-07-06 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア 異なる配列のタンパク質から形成されたアミロイドに共通する高分子量凝集中間体に対して特異的な免疫原および対応する抗体
WO2005025516A2 (en) 2003-09-12 2005-03-24 The Regents Of The University Of California Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates
JP2006508072A (ja) 2002-10-01 2006-03-09 ノースウエスタン ユニバーシティ アミロイドベータ由来拡散性リガンド（ＡＤＤＬｓ）、ＡＤＤＬ代替物、ＡＤＤＬ結合性分子、およびそれらの使用
US20040146512A1 (en) 2002-10-09 2004-07-29 Arnon Rosenthal Methods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
US20050106626A1 (en) 2002-10-20 2005-05-19 George Pieczenik Ligand binding of amyloid peptide protein epitope
KR20050086628A (ko) * 2002-11-15 2005-08-30 젠맵 에이/에스 Ｃｄ25에 대한 인간 모노클로날 항체
US20070010435A1 (en) 2002-12-19 2007-01-11 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
RU2006122946A (ru) * 2003-11-28 2008-01-10 Астразенека Аб (Se) Антитела
UA93181C2 (ru) 2004-02-23 2011-01-25 Эли Лилли Энд Компани СПОСОБ ПОЛУЧЕНИЯ АНТИТЕЛА K Ab ПЕПТИДУ
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
US20080287309A1 (en) 2004-07-10 2008-11-20 Alexion Pharmaceuticals, Inc. Methods for Discovering Antibodies Specific to Cancer Cells and Antibodies Discovered Thereby
KR20070084170A (ko) 2004-10-13 2007-08-24 아블린쓰 엔.브이. 알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드
WO2006047254A1 (en) 2004-10-22 2006-05-04 Regents Of The University Of Minnesota Assemblies of oligomeric amyloid beta protein and uses thereof
KR20070094890A (ko) 2004-10-25 2007-09-27 머크 앤드 캄파니 인코포레이티드 안티 ａｄｄｌ 항체 및 그 용도
TW200635608A (en) * 2004-12-15 2006-10-16 Neuralab Ltd Aβ antibodies for use in improving cognition
ES2371083T3 (es) * 2004-12-21 2011-12-27 Medimmune Limited Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos.
CA2589860A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
JP2008528638A (ja) 2005-01-28 2008-07-31 ワイス ポリペプチドの安定化液体処方
US20090035295A1 (en) 2005-03-05 2009-02-05 Abbott Gmgh & Co. Kg Screening Method, Process for Purifying of Non-Diffusible A-Beta Oligomers, Selective Antibodies Against Said Non-Diffusible a-Beta Oligomers and a Process for Manufacturing of Said Antibodies
ES2318918B1 (es) 2005-04-01 2010-02-16 Biotherapix Molecular Medicines, S.L.U. Anticuerpos humanos con capacidad de union al peptido beta-amiloide y sus aplicaciones.
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
WO2007062088A1 (en) 2005-11-22 2007-05-31 The Trustees Of The University Of Pennsylvania Antibody treatment of alzheimer's and related diseases
EP1976877B2 (en) 2005-11-30 2016-10-05 AbbVie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
MX358175B (es) 2005-12-12 2018-08-08 Ac Immune Sa Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas.
ATE492561T1 (de) 2006-03-23 2011-01-15 Bioartic Neuroscience Ab Verbesserte protofibrilselektive antikörper und deren verwendung
CA2673771A1 (en) * 2007-01-17 2008-07-24 Merck Serono S.A. Process for the purification of fc-containing proteins
EP2246427B1 (en) * 2008-02-08 2016-11-30 Immunas Pharma, Inc. Antibodies capable of binding specifically to amyloid beta-oligomers, and use thereof

Also Published As

Publication number Publication date
ES2610474T3 (es) 2017-04-27
AU2008204335B2 (en) 2013-06-13
WO2008084402A2 (en) 2008-07-17
PL2104682T3 (pl) 2017-03-31
TW200844110A (en) 2008-11-16
WO2008084402A3 (en) 2009-04-09
JP2010515717A (ja) 2010-05-13
EP2104682B1 (en) 2016-09-21
US20090028869A1 (en) 2009-01-29
AU2008204335A1 (en) 2008-07-17
US20120040382A1 (en) 2012-02-16
EP2104682A2 (en) 2009-09-30
DK2104682T3 (en) 2017-01-16
US20120039897A1 (en) 2012-02-16
CA2675340A1 (en) 2008-07-17
CA2675340C (en) 2018-07-31
WO2008084402A8 (en) 2009-08-27
US8491903B2 (en) 2013-07-23
US7939075B2 (en) 2011-05-10

Similar Documents

Publication Publication Date Title
SI2104682T1 (sl) Diagnostika in zdravljenje Alzheimerjeve bolezni in drugih nevrodementnih bolezni
EP2001503A4 (en) DIAGNOSIS AND TREATMENT OF MORBUS ALZHEIMER
IL208926A0 (en) Use of epothelone d in treating tau-associated diseases including alzheimer's disease
EP2369017B8 (en) Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases
EP1951892A4 (en) ANTIBODY TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES
ZA200801511B (en) Novel diazaspiroalkanes and their use for treatment of CCR8 medicated diseases
EP2429992A4 (en) TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER
EP2152318A4 (en) COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE
EP2151435A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP1817050A4 (en) DIAGNOSIS AND TREATMENT OF MORBUS ALZHEIMER
EP2091566A4 (en) COMBINATION THERAPIES AGAINST ALZHEIMER DISEASE AND SIMILAR ILLNESSES
PT2056842E (pt) Galactosil-ceramidas modificadas para coloração e estimulação de células t assassinas naturais
EP2297341A4 (en) METHOD AND COMPOSITIONS FOR TREATING MORBUS HUNTINGTON
EP2268647A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE IDENTIFICATION AND TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES
EP1962869A4 (en) TREATMENT OF RESPIRATORY DISEASES
PT2056863T (pt) Tratamento de doenças oculares
EP2306824A4 (en) IONTOPHORETIC DELIVERY OF CURCUMINE AND CURCUMINANALOGUE FOR THE TREATMENT OF MORBUS ALZHEIMER
EP2051732A4 (en) DIAGNOSIS AND TREATMENT OF METABOLIC DISORDERS AND METHODS THEREFOR
GB0608647D0 (en) Methods of diagnosis and treatment
PL1981515T3 (pl) Leczenie urazów i chorób mózgu za pomocą MAPC
EP2568811A4 (en) TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER
EP2320939A4 (en) TISSUE CALLICLE FOR THE TREATMENT OF PARKINSON DISEASE
IL213703A (en) Compounds for the treatment of pain and other diseases
WO2010105035A9 (en) Prevention, treatment, and diagnosis of alzheimer's disease through electromagnetic field exposure
EP1773882A4 (en) DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH SIGLEC-6